Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
What is the preferred concurrent chemotherapy regimen for limited stage small cell lung cancer with severe reaction to etoposide?
Related Questions
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
Would you use Razor Genomics RiskReveal molecular testing results to guide making recommendations for surgical adjuvant chemotherapy for Stage IA,IB & II non-squamous NSCLCA ?
Would you consider Amivantamab + Lazertinib combo for first line in EGFR mutated metastatic NSCLC, given the recent ESMO updates?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
In a patient with node-positive limited-stage small cell lung cancer, how do you approach radiation in a patient whose small primary tumor resolves after one cycle of chemotherapy?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
What is your approach for an RA patient with lung cancer who is starting immunotherapy?
How would you approach first-line treatment in metastatic NSCLC for a patient with ALK-EML4 V3a/b variant and MSI-high status?
Would you consider "consolidation" chemoradiotherapy for a Stage III NSCLC that was initially felt to be too extensive for definitive intent radiotherapy who later experiences a radiographic complete response to carboplatin, paclitaxel, and pembrolizumab?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
